Track 02 of 9
Bariatric Surgery
Sleeve gastrectomy, gastric bypass and metabolic surgery outcomes.
Bariatric and metabolic surgery remains the most durable intervention for class II–III obesity, with 10–20 year data from RYGB and sleeve gastrectomy demonstrating sustained weight loss, diabetes remission, and reduced all-cause mortality. The track will examine SG long-term reflux and Barrett risk, RYGB versus SG head-to-head outcomes (SLEEVEPASS, SM-BOSS), single-anastomosis duodeno-ileal bypass (SADI-S), and the rapidly maturing endoscopic sleeve gastroplasty (ESG, MERIT trial). Sessions will also address combination therapy — surgery plus GLP-1 RA — and revisional strategies for weight regain.
Focus areas
- RYGB vs sleeve gastrectomy: 10-year SLEEVEPASS, SM-BOSS, STAMPEDE
- Endoscopic sleeve gastroplasty (ESG): MERIT trial and durability
- SADI-S and duodenal switch for super-obesity and diabetes
- Post-sleeve GERD, Barrett surveillance and conversion to RYGB
- Revisional surgery and pharmacotherapy for weight regain
- Metabolic surgery in BMI 30–35 with type 2 diabetes
- Lean mass and bone density preservation post-bariatric